Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Kivu Bioscience Inc.
Instil Bio
AstraZeneca
BeOne Medicines
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Exelixis
BeOne Medicines
Astellas Pharma Inc
Institut Claudius Regaud
National Institutes of Health Clinical Center (CC)
BioNTech SE
Kura Oncology, Inc.
Zymeworks BC Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AstraZeneca
AbbVie
Johnson & Johnson Enterprise Innovation Inc.
Eli Lilly and Company
Iambic Therapeutics, Inc
Amgen
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
EMD Serono
Plexium, Inc.
The Methodist Hospital Research Institute
OncoC4, Inc.
Deciphera Pharmaceuticals, LLC
Revolution Medicines, Inc.
Novartis
Exscientia AI Limited
USWM, LLC (dba US WorldMeds)
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
KaliVir Immunotherapeutics
Pfizer
Pfizer
Astellas Pharma Inc
Fate Therapeutics
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca
National Institutes of Health Clinical Center (CC)